Reference : Pharmacological effects of tiludronate in horses after long-term immobilization
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Life sciences : Veterinary medicine & animal health
Pharmacological effects of tiludronate in horses after long-term immobilization
Delguste, Catherine mailto [Université de Liège - ULiège > Département de sciences fonctionnelles > Pharmacologie, pharmacothérapie et toxicologie >]
Amory, Hélène mailto [Université de Liège - ULiège > Département clinique des animaux de compagnie et des équidés > Médecine interne des équidés >]
Doucet, Michèle [Université de Montréal - UdeM > Biomédecine > > >]
Piccot-Crezollet, C. [> > > >]
Thibaud, D. [> > > >]
Garnero, P. [> > > >]
Detilleux, Johann mailto [Université de Liège - ULiège > Département de productions animales > Génétique quantitative >]
Lepage, O. M. [> > > >]
Elsevier Science Inc
Yes (verified by ORBi)
New York
[en] horse ; bisphosphonate ; bone densitometry ; bone turnover ; immobilization model
[en] Introduction: Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical biomarkers of bone metabolism and on bone density and structure in an experimental model of disuse osteoporosis induced by cast application in horses. Methods: Two groups of eight horses were immobilized during 8 weeks. The first group (P-group) received a placebo, and the second group (T-group) received tiludronate 1 mg/kg by slow IV infusion. Both treatments were administered twice, 28 days apart. Immobilization consisted of stall rest with the left forelimb packed in a fiberglass cast. It was followed by a 4-week remobilization period and an 8-week standardized training protocol. One biomarker of bone resorption, the C-telopeptides of type 1 collagen cross-links (CTX-1) and one biomarker of bone formation, the bone isoenzyme of alkaline phosphatase (bone ALP), were assessed. Metacarpus III (MCIII) bone mineral density (BMD) and speed of sound (SOS) were evaluated respectively by dual energy X-ray absorptiometry (DEXA) and quantitative ultrasonography (QUS). Lameness was regularly assessed during the remobilization and training periods. Group- and time-related effects were tested by analysis of variance on repeated measurements. Results: A rapid, transient and significant decrease in CTX-1 concentration was seen after each treatment in the T-group only. No significant differences between groups were seen in the evolution of bone ALP activity. At the end of the experiment, the loss of MCIII BMD measured by DEXA in the immobilized limb was significantly less in the T-group than in the P-group. The MCIII SOS measured by QUS did not significantly vary within or between groups throughout the study. Discussion and conclusions: Tiludronate was found to significantly reduce bone resorption during immobilization, as well as to prevent long-term osteopenia in the immobilized limb. Disuse osteopenia did not affect the lateral superficial cortex of MCIII. (C) 2007 Elsevier Inc. All rights reserved.
CEVA Santé Animale
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Restricted access
BON7808.pdfPublisher postprint418.57 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.